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Abstract
Background: Targeted therapies for metastatic renal cell carcinoma (RCC), including mammalian target of
rapamycin (mTOR) inhibitors and small-molecule multikinase inhibitors, have produced clinical effects. However,
most patients acquire resistance over time. Thus, new therapeutic strategies need to be developed. Here, we
evaluated the effect of the dual PI3K/mTOR inhibitor NVP-BEZ235, in combination with the multikinase inhibitor
sorafenib on renal cancer cell proliferation and survival in vitro as well as on tumor growth in vivo.
Methods: The renal carcinoma cell lines 786-0 and Caki-1 were treated with NVP-BEZ235 or sorafenib, either alone
or in combination. Tumor cell proliferation and apoptosis were investigated in vitro. The anticancer efficacy of NVP-
BEZ235 alone, or in combination with sorafenib, was also evaluated on RCC xenografts in nude mice.
Results: Treatment of 786-0 and Caki-1 cells with NVP-BEZ235 or sorafenib resulted in reduced tumor cell
proliferation and increased tumor cell apoptosis in vitro. The combination of NVP-BEZ235 and sorafenib was more
effective than each compound alone. Similarly, in vivo, NVP-BEZ235 or sorafenib reduced the growth of xenografts
generated from 786-0 or Caki-1 cells. The antitumor efficacy of NVP-BEZ235 in combination with sorafenib was
superior to NVP-BEZ235 or sorafenib alone.
Conclusions: Our findings indicate that the simultaneous use of NVP-BEZ235 and sorafenib has greater antitumor
benefit compared to either drug alone and thus provides a treatment strategy in RCC.
Introduction
Renal cell carcinoma (RCC) is a highly vascularized
tumor which accounts for 3% of all malignancies in
adults [1]. Most symptomatic patients present with
advanced metastatic disease, which has a poor prog-
nosis. Traditional chemotherapy, hormonal therapy or
radiation are not effective in the treatment of advanced
RCC, and immunotherapy (including IL-2 and inter-
feron-a) provides only limited benefit [2]. Nevertheless,
based on the molecular biology of RCC, new therapeutic
strategies have recently emerged in the management of
advanced disease. Indeed, a characteristic of RCC is the
frequent inactivation of the Von Hippel Lindau protein
(pVHL), which occurs in 50 to 60 percent of patients
with sporadic RCC [3]. The molecular consequences of
pVHL mutations result in the upregulation of Hypoxia-
Inducible Factor-1a (HIF-1a) which induces the tran-
scription of hypoxia responsive genes such as Vascular
Endothelial Growth Factor (VEGF) [4]. In consequence,
loss of pVHL results in VEGF production and induction
of angiogenesis.
Encouraging clinical studies show that agents targeting
VEGF and tumor angiogenesis significantly prolong pro-
gression-free survival in patients with RCC [1,5]. Among
those agents, sorafenib has been approved for the treat-
ment of advanced RCC [6]. Initially identified as a Raf
kinase inhibitor, sorafenib also blocks the kinase activ-
ities of several receptors including VEGF receptor 1, 2,
3 and platelet derived growth factor receptor beta [7].
Sorafenib exhibits antitumor activity in several experi-
mental models of renal cancer, primarily by inhibiting
angiogenesis [8].
In addition to sorafenib, allosteric inhibitors of the
mammalian target of rapamycin (mTOR) have also
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been approved for the treatment of advanced RCC.
The rationale of targeting mTOR in RCC is related to
the observation that mTOR regulates the expression of
HIF-1a [9]. Two such inhibitors, temsirolimus [10]
and everolimus [11], have significant activity in
patients with advanced RCC and prolong the progres-
sion-free survival. However, the responses are short
lived and most of the patients finally develop resistance
[12]. These limited benefits observed in clinical trials
are partially explained by experimental evidences
where treatment of cells with rapamycin, or its analogs
temsirolimus and everolimus, activates the PI3K/Akt
signaling pathway by the removal of a negative feed-
back loop [13]. In turn, the activation of PI3K/Akt
results in the activation of proliferative and pro-survi-
val signals that counteract the anticancer efficacy of
rapamycin. Furthermore, mTOR exists in two different
complexes, mTORC1 and mTORC2. While mTORC1
is sensitive to rapamycin, mTORC2 is not [14]. Finally,
not all the functions of mTORC1 are targeted by rapa-
mycin [15]. To overcome these limitations, a new gen-
eration of agents targeting the ATP-binding domain of
mTOR and inhibiting both mTORC1 and mTORC2
has been developed [16]. Among these agents, NVP-
BEZ235 is a dual PI3K/mTOR inhibitor currently in
clinical development [17]. The antitumor efficacy of
NVP-BEZ235 has been demonstrated in numerous pre-
clinical models [18-20], including RCC where its antic-
ancer efficacy is shown to be superior to rapamycin
[21]. Interestingly, NVP-BEZ235 has little effect on
tumor angiogenesis in RCC suggesting that its antitu-
mor efficacy may be potentiated in combination with
anti-angiogenic therapy [21].
Despite having improved the clinical outcome of
patients with RCC, targeted therapies are not associated
with long lasting responses. Consequently, there is a
strong need to develop new therapeutic strategies for
the treatment of RCC. In this report, we have analyzed
the effects of NVP-BEZ235 in combination with the
anti-angiogenic compound sorafenib on renal cancer
cell lines in vitro and on renal tumor xenografts in vivo.
Material and Methods
Cell lines, antibodies and reagents
The human renal cell carcinoma cell lines 786-0 and
Caki-1 were obtained from the American Type Culture
Collection and cultured in DMEM medium supplemen-
ted with 10% fetal bovine serum (FBS) and 1% penicil-
lin-streptomycin. Cells were incubated at 37°C at 5%
CO2. Antibodies directed against phospho-Akt (S473),
Akt, phospho-S6 ribosomal protein (Ser235/236), S6
ribosomal protein, phospho-MAPK (Thr202/Tyr204),
MAPK, cleaved caspase-3 and actin were from Cell Sig-
naling. Antibody against CD31 was purchased from BD
Biosciences. NVP-BEZ235 and sorafenib were purchased
from LC Laboratories.
Cell count
Cells were plated in six-well plates (Costar) at a density
of 100 000 cells/well and cultured in DMEM 10% FBS.
Twelve hours later, cells were treated with increasing
doses of NVP-BEZ235 (10-1000 nM), sorafenib (10 μM),
a combination of both or DMSO as a control for 48 or
72 hours. Subsequently, adherent cells were collected
and trypan-blue negative cells were counted using a
Neubauer hemocytometer.
MTS proliferation assay
Caki-1 or 786-0 cells were plated on 96-well plates
(Costar) at 10’000 cells per well and cultured in DMEM
10% FBS. Twelve hours later, cells were treated with
NVP-BEZ235 1 μM, sorafenib 10 μM, a combination of
both or DMSO as a control. Cellular proliferation was
monitored after 48 or 72 hours of treatment with the
CellTiter 96® AQueous One Solution (Promega Corpora-
tion) colorimetric assay by following the manufacturer’s
instructions. The MTS compound is reduced by living
cells into a formazan product whose quantity is directly
proportional to the number of cells in culture. The
quantity of formazan product is measured by the
amount of 490 nm absorbance.
BrdU incorporation assay
Cells were plated on coverslips and treated with the
indicated inhibitor for 24 hours. 5-bromo-2’-deoxyuri-
dine (BrdU) at a final concentration of 10 μM was
added to the culture medium for the last 12 hours. Sub-
sequently, cells were fixed with paraformaldheyde (4%)
for 10 min, washed twice with PBS and incubated with
HCl 2 N for 2 min. Cells were extensively washed in
PBS and immunocytofluorescence was done with mouse
anti BrdU antibody (DAKO), and the fluorochrome con-
jugated secondary antibody against mouse Ig (alexa 594,
Invitrogen). The nuclei were counterstained with DAPI.
Immunostained cells were observed under epifluorescent
microscope IX81 (Olympus). BrdU and DAPI positive
cells were counted using a computer-assisted image ana-
lysis station (Mercator, Explora Nova). Results were
expressed as the ratio of BrdU- to DAPI-positive cells.
Apoptosis Assay
The Cell Death Detection ELISAplus kit (Roche) was
used to measure apoptosis. Caki-1 and 786-0 cells were
seeded in 96-well plates at 30,000 cells per well and
grown in serum-free medium at 37°C. Twelve hours
later, cells were treated with NVP-BEZ235 (1 μM), sora-
fenib (10 μM), a combination of both, or DMSO as a
control, for 24 hours. Subsequently cells were harvested
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and apoptosis was determined following the manufac-
turer’s instructions. Results are represented as the mean
enrichment factor (absorbance of the treated cells/absor-
bance of the control cells).
Cell cycle analysis
Caki-1 and 786-0 cells were treated with NVP-BEZ235
(1 μM), sorafenib (10 μM), a combination of both, or
DMSO as a control for 48 hours. Cells were collected
and processed for FACS analysis as previously
described [22].
Western Blot Analysis
Western Blot analysis were performed as previously
described [22].
Xenograft model
Animal experiments were in accordance with the Swiss
federal animal regulations and approved by the local
veterinary office. Female nude eight-week old mice were
purchased from Charles River Laboratories. Caki-1 or
786-0 cells at 3 × 106 were injected subcutaneously into
the flank. Once the tumor xenografts reached 25 mm3
mice were randomized into different groups (n = 5/
group) and treated once daily by gavage with vehicle,
Sorafenib (15 mg/kg/day), NVP-BEZ235 (30 mg/kg/day),
or in combination. NVP-BEZ235 was solubilized in one
volume of N-methylpyrrolidone and further diluted in
nine volumes of PEG 300. Sorafenib was dissolved in
Cremophor EL/ethanol (Sigma) at 4-fold (4×) and
further diluted to 1× with water. Tumor volumes were
measured using caliper measurements every day and cal-
culated with the formula V = π/(6a2b) where a is the
short axis and b the long axis of the tumor. Animals
were sacrificed after 20 days of treatment and the
tumors were excised and weighed.
Immunochemistry
Tumor xenografts were carefully removed and rapidly
frozen in OCT compound (Tissue-Teck) on dry ice. Ten
μm transverse sections were cut on a cryostat (CM
1850, Leica), and processed for immunolabeling with an
anti-CD31 antibody (1:20, MEC13.3, BD Biosciences) as
previously described [23]. Vessels were manually
counted in five high-power fields (HPF) in each tumor.
In addition, immunolabeling with an anti-Ki-67 (Novo-
castra) antibody was also performed as described by
others [24].
Statistical analysis
Comparisons between groups were done using one-way
ANOVA followed by Dunnett’s post-hoc test. Compari-
sons between groups for tumor volume progression
were done using repeated measures ANOVA. All
calculations were done using IBM SPSS Statistics 18.
Values of p < 0.05 were considered statistically
significant.
Results
Antitumor activity of NVP-BEZ235 alone or in
combination with sorafenib on 786-0 and Caki-1 cells in
vitro
To evaluate the efficacy of combined NVP-BEZ235 and
sorafenib treatment on renal cancer cell, 786-0 and
Caki-1 cells were exposed to NVP-BEZ235 and sorafe-
nib either alone or in combination for 48 and 72 hours
and analyzed by MTS assay. Growth of 786-0 and
Caki-1 cells was significantly inhibited by each drug
alone (Figure 1A). The combination of both drugs
further significantly decreased renal cancer cell growth
compared to single drug treatment. NVP-BEZ235 was
used at a concentration of 1 μM which proved to be
efficient in inhibiting mTORC1 and mTORC2 as
assessed by the inhibition of the phosphorylation of S6
ribosomal protein and Akt, downstream effectors of
mTORC1 and mTORC2 respectively (Figure 1B). Simi-
larly, cells were exposed to 10 μM of sorafenib, a con-
centration at which sorafenib reduced Raf kinase
activity as observed by the reduction of MAPK phos-
phorylation (Figure 1C).
Effect of NVP-BEZ235 alone or in combination with
sorafenib on renal cancer cell proliferation
We next performed proliferation assays to determine
whether the reduction in cell growth observed with
NVP-BEZ235 and sorafenib (Figure 1A) was due to a
reduction in cell proliferation. 786-0 cells were exposed
to NVP-BEZ235 or sorafenib, alone or in combination
and cell number was determined after 48 or 72 hours of
treatment. We observed that NVP-BEZ235 as well as
sorafenib significantly reduced 786-0 cell number after
48 and 72 hours compared to untreated cells (Figure
2A). Similarly, BrdU incorporation was more signifi-
cantly reduced in cells treated simultaneously with
NVP-BEZ235 and sorafenib compared to cells treated
with NVP-BEZ235 or sorafenib alone (Figure 2B and
2C). Similar results were obtained with Caki-1 cells
(data not shown). Collectively these results suggest that
the antiproliferative efficacy of NVP-BEZ235 or sorafe-
nib on renal cancer cell is significantly improved when
both drugs are used simultaneously.
Effect of NVP-BEZ235 alone or in combination with
sorafenib on renal cancer cell apoptosis
We further analyzed the potential of NVP-BEZ235
alone or in combination with sorafenib to induce renal
cancer cell apoptosis. 786-0 and Caki-1 cells were trea-
ted with NVP-BEZ235, sorafenib or a combination of
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Figure 1 NVP-BEZ235 and Sorafenib inhibit the growth of renal cancer cell lines. A, 786-0 and Caki-1 cellular growth was monitored with
colorimetric MTS assay after 48 hours of treatment with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or
DMSO (Control). Columns, mean cell viability relative to control of four independent experiments; bars, SD. *, P < 0.05, **, P < 0.01, #, P < 0.001
compared to control, or otherwise as specified by brackets. B, NVP-BEZ235 inhibits PI3K/mTOR pathway in renal cancer cells. 786-0 and Caki-1
cells were treated with increasing doses of NVP-BEZ235 or DMSO (Control) for 4 hours. Cells were subsequently lysed and lysates were examined
for phospho-Akt (Ser 473), Akt, phospho-S6 (Ser 235/236) or S6 expression level by Western blot analysis. C, 786-0 and Caki-1 cells were treated
with increasing doses of sorafenib or DMSO as a control for 4 hours. Cells were processed as under panel B and analyzed for phospho-MAPK
and MAPK (Thr202/Tyr204). The illustrated blots are representative of three similar experiments.
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Figure 2 Effect of NVP-BEZ235 alone or combined with Sorafenib on renal cancer cell proliferation. A, 786-0 cells were treated with NVP-
BEZ235 (NVP; 1 μM) alone or combined to Sorafenib (Soraf; 10 μM). Cells were counted after 48 or 72 hours of treatment as described under
Materials and Methods. Columns, mean cell count of three independent experiments; bars, SD. B, BrdU uptake of 786-0 cells treated with NVP-
BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control), for 24 hours. Results are quantified as
percentage of positive 786-0 cells for BrdU incorporation. Columns, mean percentage of three independent experiments; bars, SD. C, samples
processed and analyzed under a fluorescence microscope. (Magnification 100×. Scale bar 100 μm). *, P < 0.05, #, P < 0.001 compared to control,
or otherwise as specified by brackets.
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both and cell apoptosis was determined after 24 hours
of treatment using a cell death detection ELISA. NVP-
BEZ235 and to a lesser extend sorafenib induced apop-
tosis as reflected by an increased DNA fragmentation
in 786-0 and Caki-1 cells. This pro-apoptotic effect
was also potentiated when both drugs were used in
combination compared to single therapy (Figure 3A).
Consistent with this finding, we also found by cell
cycle analysis that combined therapy resulted in a
more prominent sub-G1 population when compared to
monotherapy (Figure 3B). Taken together these results
show that the pro-apoptotic effect of NVP-BEZ235 in
combination with sorafenib is superior to single
treatment.
Effect of NVP-BEZ235 alone or in combination with
sorafenib on the growth of renal cancer xenografts
We next studied the effect of NVP-BEZ235 alone or in
combination with sorafenib on the growth of 786-0 and
Caki-1 xenografts. Nude mice bearing 786-0 or Caki-1
tumor xenografts were treated with NVP-BEZ235, sora-
fenib or a combination of both drugs for 20 days. We
used low doses of NVP-BEZ235 (30 mg/kg/day) since
we observed in preliminary studies that these were suffi-
cient to block mTORC1 and mTORC2 in tumor xeno-
grafts (data not shown). In addition, we used 15 mg/kg/
day of sorafenib which has been previously shown to
reduce the growth of renal cancer xenografts [8]. The
tumor size (Figure 4A) and weight (Figure 4B) of NVP-
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Figure 3 Effect of NVP-BEZ235 alone or combined with Sorafenib on renal cancer apoptosis. A, 786-0 (left panel) or Caki-1 cells (right
panel) were treated for 24 hours with NVP-BEZ235 (NVP, 1 μM) or Sorafenib (Soraf, 10 μM) either alone or in combination, or DMSO (Control).
Cells were harvested and apoptosis was measured by quantifying DNA fragmentation. Columns, mean enrichment factor at 405 nm of three
independent experiments; bars, SD. B, 786-0 and Caki-1 cells were treated as in A for 48 hours and processed for cell cycle analysis. One of three
similar experiments is shown. *, P < 0.05, **, P < 0.01, #, P < 0.001 compared to control, or otherwise as specified by brackets.
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Figure 4 Effect of NVP-BEZ235 alone or combined with Sorafenib on the growth of 786-0 and Caki-1 xenografts. A, An equal amount of
786-0 (left panel) or Caki-1 (right panel) cells were harvested and injected subcutaneously into nude mice. Once the tumor reached 25 mm3
mice were randomized into four groups and treatments were started with vehicle (Control), NVP-BEZ235 (NVP, 30 mg/kg/day po), Sorafenib
(Soraf, 15 mg/kg/day po), or a combination of both (NVP+Soraf). Five mice were included in each group. Tumor volumes were evaluated using
caliper measurements and calculated with the formula V = π/6 × a2 × b where a is the short axis and b the long axis of the tumor. Points,
mean value of tumor volume; bars, SD. B, After 20 days of treatment, mice were sacrificed, tumor xenografts were harvested and tumor weight
was measured. Columns, mean tumor weight (five tumor xenografts in each group); bars, SD. *, P < 0.05, #, P < 0.001 compared to control, or
otherwise as specified by brackets. C, Body weights of mice were measured to assess toxicity of the treatments. Points, mean body weight (five
mice in each groups); bars, SD.
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BEZ235- or sorafenib-treated xenografts were signifi-
cantly smaller in comparison with untreated (control)
xenografts. Moreover, the growth of combined NVP-
BEZ235 and sorafenib treated xenografts was signifi-
cantly reduced when compared to monotherapy. Over-
all, the treatments were tolerated without evident
toxicity. All animals survived after 20 days of treatment
and no significant body weight loss was observed (Figure
4C). Taken together, these results show that the anti-
cancer efficacy of NVP-BEZ235 combined with sorafenib
is greater than either drug used alone.
Effect of NVP-BEZ235 alone or in combination with
sorafenib on tumor cell proliferation and survival and
tumor angiogenesis
To better understand the mechanism of action of NVP-
BEZ235 and sorafenib in vivo, tumor xenografts were
harvested after 20 days of treatment and processed for
various analysis. Immunostainings of Ki-67 and CD31
were used to determine tumor cell proliferation and
angiogenesis respectively. Western Blot analysis of
tumor xenografts for cleaved caspase-3 expression was
used to detect cell apoptosis. NVP-BEZ235 reduced cell
proliferation and induced apoptosis in both 786-0 and
Caki-1 tumor xenografts (Figure 5A and 5B). NVP-
BEZ235 slightly decreased tumor vasculature which was
only significant in 786-0 xenografts (Figure 5C). Sorafe-
nib had no effect on tumor cell proliferation and did
not induce cleaved caspase-3 expression. However, sora-
fenib significantly reduced tumor angiogenesis. Combin-
ing NVP-BEZ235 and sorafenib had no additive effects
on tumor cell proliferation and tumor angiogenesis. In
contrast, cleaved caspase-3 expression was increased
when mice were treated concomitantly with NVP-
BEZ235 and sorafenib compared to NVP-BEZ235 alone.
Taken together these results suggest that, in 786-0 and
Caki-1 tumor xenografts, sorafenib potentiates the pro-
apoptotic efficacy of NVP-BEZ235.
Effect of treatment interruption on tumor growth
To next determine the effect on tumor growth induced
by the discontinuation of drug administration, nude
mice bearing 786-0 cell xenografts were treated with
NVP-BEZ235, sorafenib or a combination of both for 10
days. At day 10, drug administration was stopped and
tumor growth was monitored for an additional 10 days.
We observed that the growth of 760-0 tumor xenografts
was still reduced five days after drug interruption, prob-
ably reflecting residual inhibition. However, tumors sig-
nificantly started to grow after 5 days without treatment
(Figure 6A). The relative tumor growth was also signifi-
cantly increased in treated mice compared to untreated
mice. The relative tumor growth was further augmented
when mice were treated simultaneously with NVP-
BEZ235 and sorafenib (Figure 6B).
Discussion
In this study, we described the antitumor activity of
NVP-BEZ235 in combination with sorafenib in renal
cancer cells. In vitro, the antiproliferative and the pro-
apoptotic efficacy of NVP-BEZ235 and sorafenib was
significantly increased when both drugs were used in
combination compared to monotherapy. Similarly, in
vivo, the inhibition of tumor growth was greater when
both drugs were applied simultaneously compared to
either drug alone.
Targeted therapies, including sorafenib, sunitinib, bev-
acizumab, and mTOR inhibitors, have revolutionized the
treatment of metastatic RCC [1]. However, none of
these therapies induce complete responses and most of
the patients ultimately progress during therapy [12].
Therefore, new strategies are needed to achieve com-
plete responses and block the onset of refractory disease.
As it has become evident that most tumors can escape
from the inhibition of a single agent, the combination of
different targeted agents represent a promising approach
[25,26]. Our study showed that combining NVP-
BEZ235, a dual PI3K/mTOR inhibitor, and sorafenib
might represent a therapeutic strategy in advanced RCC.
Consistent with our finding, experimental studies have
already shown that combining allosteric inhibitors of
mTOR such as rapamycin with sorafenib increases the
antitumor effect of both drugs [27]. Clinical trials are
currently evaluating the efficacy of this treatment regi-
men in advanced RCC. Our study further shows that,
despite being more potent than rapamycin, the antitu-
mor efficacy of NVP-BEZ235 can also be potentiated in
combination with sorafenib.
The mechanism of action of sorafenib has been par-
tially characterized. Since sorafenib is a multi-kinase
inhibitor that blocks several targets including VEGFR-1,-
2,-3, PDGFRb and Raf kinases, the molecular mechan-
isms involved in the antitumor activity of sorafenib
might be complex. In our in vitro experiments, we
observed that sorafenib at 10 μM reduced the phosphor-
ylation of MAPK suggesting that it acts as a Raf kinase
inhibitor. In addition, we also found that sorafenib
potentiated the anti-proliferative and pro-apoptotic effi-
cacy of NVP-BEZ235 which targets PI3K/Akt/mTOR
signaling pathway. Consistent with this observation, pre-
vious studies have shown that the antitumor activity of
mTOR inhibitors is increased when the Raf/MAPK sig-
naling pathway is concomitantly inhibited [28]. In vivo,
sorafenib did not reduce cancer cell proliferation and
did not induce cancer cell apoptosis. We rather
observed that sorafenib reduced tumor angiogenesis
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Tumor lysates were generated from xenografts and analyzed for cleaved caspase-3 and actin expression. C, Frozen sections of tumor xenografts
were stained with an anti-CD31 antibody. Vessels were manually counted in five high-power fields (HPF) in each tumor. Columns, mean vessel
number per HPF (three tumor xenografts analyzed in each group); bars, SD. *, P < 0.05, #, P < 0.001 compared to control.
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suggesting that the mechanism of action of sorafenib is
different in vitro and in vivo.
The rationale to use NVP-BEZ235 with agents target-
ing angiogenesis is also based on the observation that
NVP-BEZ235 has little effect on tumor angiogenesis in
xenograft models of RCC. Targeting the PI3K/Akt sig-
naling pathway provides opposite effects on angiogenesis
depending on the model used. On one hand, blocking
endothelial Akt with rapamycin results in reduced
angiogenesis and NVP-BEZ235 decreases VEGF-induced
angiogenesis [29-31]. On the other hand, tumors
implanted into transgenic mice lacking Akt grow faster
and present an increased vasculature [32]. Therefore the
angiogenic effect of the inhibition of the PI3K/Akt sig-
naling pathway in endothelial cells may be unpredict-
able. In this study, we found that NVP-BEZ235 only
slightly reduced tumor angiogenesis in 786-0 xenografts.
A similar effect was observed in Caki-1 xenografts
which was, however, not significant. Consistently, no
reduction of tumor angiogenesis was found in RCC
xenografts treated with NVP-BEZ235 [21]. Furthermore,
an increase of tumor angiogenesis has been described in
786-0 xenografts treated with LY294002, a PI3K inhibi-
tor [33]. Therefore, agents that target the PI3K/Akt
pathway have little effect on tumor angiogenesis in renal
cancer xenograft models. This suggests that their antitu-
mor efficacy might be increased in combination with
anti-angiogenic drugs.
Different options of combination therapy exist, includ-
ing the inhibition of different targets in the same path-
way (vertical blockade), or the inhibition of two separate
pathways (horizontal blockade) [26]. As NVP-BEZ235
inhibits multiple effectors in the PI3K/Akt/mTOR sig-
naling pathway, a simultaneous vertical and horizontal
blockade is achieved by combining NVP-BEZ235 and
sorafenib. The potential problem of such combination
therapy is the increased toxicity. Although we did not
find any evident toxicity, further studies are required to
fully characterize the toxicity profile of this treatment.
In particular, side effects should be monitored over a
longer period of time.
It was previously reported that NVP-BEZ235 failed to
induce renal cancer cell apoptosis in vitro [21]. How-
ever, we found here that treatment of 786-0 and Caki-1
cells with NVP-BEZ235 resulted in cell apoptosis as
observed by ELISA assay and FACS analysis. In contrast
to Cho et al, we performed our apoptotic experiments
in the absence of serum which could explain the contra-
dictory results. In fact, we also found that in presence of
serum NVP-BEZ235 failed to induce apoptosis of 786-0
and Caki-1 cells (data not shown).
RCC is often associated with a loss of function of
pVHL. Previous reports showed that loss of pVHL sensi-
tized renal cancer cells to allosteric inhibitors of mTOR
[34]. In this report, we found that NVP-BEZ235 inhib-
ited the growth of VHL -/- 786-0 as well as VHL+/+
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Figure 6 Effect of treatment cessation on tumor growth. A, An equal amount of 786-0 cells were injected subcutaneously into nude mice.
Once the tumor reached 25 mm3 mice were randomized into four groups and treatments were started with vehicle (Control), NVP-BEZ235 (NVP,
30 mg/kg/day po), Sorafenib (Soraf, 15 mg/kg/day po), or a combination of both (NVP+Soraf). After 10 days, treatments were stopped and
tumor growth was further monitored. Points, mean value of tumor volume; bars, SD. Five mice were analyzed in each group. B, Relative tumor
volumes (normalized to their size at day 5 off-treatment) at day 10 off-treatment. *, P < 0.05 compared to control.
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Caki-1 cells both in vitro and in vivo, suggesting that
NVP-BEZ235 blocks the growth of renal cancer cells
regardless of their VHL status. In addition, we also
observed that combining NVP-BEZ235 with sorafenib
resulted in increased antitumor effects in both cell lines
supporting the hypothesis that this therapeutic approach
may be effective independently of pVHL status.
Conclusions
In summary, we reported that the anticancer efficacy of
NVP-BEZ235 is potentiated by sorafenib in the context
of RCC. Indeed, combining NVP-BEZ235 with sorafenib
showed increased antitumor efficacy compared to either
drug alone in renal cancer xenografts. Combination
treatment also lead to enhanced apoptosis and reduction
of renal cancer cell proliferation compared to single
therapy. Our results therefore provide a novel treatment
strategy in RCC that could be used for the design of
clinical studies.
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